Cantor Fitzgerald Reiterates Overweight on Biogen, Maintains $311 Price Target
Portfolio Pulse from Benzinga Newsdesk
Cantor Fitzgerald analyst Eric Schmidt has reiterated an Overweight rating on Biogen (NASDAQ:BIIB) and maintained a price target of $311.
February 20, 2024 | 5:33 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Cantor Fitzgerald reaffirms an Overweight rating on Biogen, with a $311 price target.
The reiteration of an Overweight rating and maintenance of a high price target by a reputable analyst like Eric Schmidt from Cantor Fitzgerald could signal strong confidence in Biogen's future performance. This endorsement is likely to positively influence investor sentiment and potentially lead to a short-term increase in BIIB's stock price.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100